NCT06035133View on ClinicalTrials.gov

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

NANot yet recruitingINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

November 10, 2024

Study Completion Date

November 10, 2027

Conditions
Rectal Cancer
Interventions
DRUG

CapeOX + cetuximab

CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.

DRUG

CapeOX + bevacizumab

CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.

RADIATION

radiotherapy

radiotherapy

All Listed Sponsors
lead

Tang-Du Hospital

OTHER

NCT06035133 - Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy | Biotech Hunter | Biotech Hunter